Global Left Atrial Appendage Closure Devices Market

Left Atrial Appendage Closure Devices Market Size, Share, Growth Analysis, By Product(Endocardial LAA Devices, Epicardial LAA Devices), By Procedure(Percutaneous, Surgical), By End - Use(Hospitals, Ambulatory Surgical Centers) - Industry Forecast 2024-2031

Report ID: SQMIG35A2586 | Region: Global | Published Date: March, 2024
Pages: 184 | Tables: 88 | Figures: 66

Share your requirements to help us to customize the report.

I acknowledge that I have read the Privacy Policy

Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

License Type Top market research company in USA

File Type

Analyst Support

$5,300

BUY NOW GET FREE SAMPLE

FAQs

Left Atrial Appendage Closure Devices Market size was valued at USD 1.21 billion in 2022 and is poised to grow from USD 1.46 billion in 2023 to USD 6.48 billion by 2031, growing at a CAGR of 20.5% in the forecast period (2024-2031).

The competitive landscape of the left atrial appendage closure devices market is characterized by intense rivalry among established players and a surge of new entrants vying for market share. Leading companies such as Boston Scientific Corporation, Abbott Laboratories, and AtriCure, Inc. dominate the market with their comprehensive product portfolios, extensive research capabilities, and strategic alliances. These industry giants are focused on continuous product innovation, robust clinical trials, and strategic collaborations to maintain their competitive edge. 'Boston Scientific Corporation (USA)', 'Abbott Laboratories (USA)', 'AtriCure, Inc. (USA)', 'Johnson & Johnson (USA)', 'Lifetech Scientific (China)', 'Occlutech International AB (Sweden)', 'Artio Medical (USA)', 'Cardia, Inc. (USA)', 'SentreHEART, Inc. (USA)', 'Lepu Medical Technology Co., Ltd. (China)'

The increasing prevalence of atrial fibrillation, a major risk factor for stroke and heart-related complications, is a significant driver for the adoption of left atrial appendage (LAA) closure devices.

Transition to Minimally Invasive Procedures: The trend towards minimally invasive interventions is driving the shift from open-heart surgeries to minimally invasive LAA closure procedures, resulting in reduced patient recovery time and hospital stays.

In 2022, North America dominated the revenue landscape with a share exceeding 45.0%, driven by a surge in atrial fibrillation cases. The region is poised to maintain a significant stance in the left atrial appendage (LAA) devices market. According to CDC estimates, between 2.7 million and 6.1 million Americans were affected by atrial fibrillation in 2019, a figure poised to escalate alongside the aging population trend.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Left Atrial Appendage Closure Devices Market Size, Share, Growth Analysis, By Product(Endocardial LAA Devices, Epicardial LAA Devices), By Procedure(Percutaneous, Surgical), By End - Use(Hospitals, Ambulatory Surgical Centers) - Industry Forecast 2024-2031

Share your requirements to help us to customize the report.

Confidentiality

FAQs

What is the market size of Left Atrial Appendage Closure Devices Market?

Who are the key vendors in the Left Atrial Appendage Closure Devices Market?

What is the key driver of Left Atrial Appendage Closure Devices Market?

What is the key market trend for Left Atrial Appendage Closure Devices Market?

Which region accounted for the largest share in Left Atrial Appendage Closure Devices Market?

Related Reports

Feedback From Our Clients

$5,300